Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
200 shown of 8,648 total abstracts
  1. Abstract 10572026-04-04 · 13:30 CT · E450
    PALOMA-125: Ibrance (palbociclib) maintenance in HR+ breast cancer
    R. Herbst, M. Krop, H. Rugo, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 96152026-04-03 · 18:45 CT · S100A
    DESTINY-Breast-427: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    H. Rugo, T. Mok, A. Spira · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  3. Abstract 46152026-04-03 · 18:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-537 study)
    N. Rizvi, S. Peters, S. Modi · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  4. Abstract 19242026-04-01 · 18:30 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    G. Curigliano, J. Cortes, P. Schmid, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 16952026-04-05 · 15:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-255 study)
    A. Spira, M. Krop, C. Saura · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 12472026-04-02 · 20:00 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    S. Antonia, F. Andre · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 96812026-04-05 · 14:30 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    F. Andre, S. Tolaney, N. Rizvi, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 69772026-04-04 · 15:30 CT · S100A
    Quality of life outcomes with Opdivo in patients with RCC
    J. Cortes, S. Peters, M. Reck · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  9. Abstract 10752026-04-01 · 14:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-911
    R. Herbst, E. Winer, N. Rizvi, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 44892026-04-03 · 15:30 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-585
    E. Winer, C. Saura · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 10522026-04-03 · 16:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-182 study)
    S. Antonia, G. Curigliano · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 99112026-04-03 · 19:00 CT · S100A
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-673
    S. Peters, C. Robert, T. Mok, et al. · Cleveland Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  13. Abstract 17932026-04-03 · 18:15 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    M. Krop, S. Antonia, J. Brahmer · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 90372026-04-03 · 18:30 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-775 study)
    P. Schmid, A. Spira · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 17182026-04-04 · 15:30 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Antonia, S. Tolaney · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 50152026-04-05 · 13:00 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-363
    S. Tolaney, C. Saura, S. Antonia, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  17. Abstract 48222026-04-02 · 13:45 CT · S100A
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-295
    G. Curigliano, J. Cortes, S. Antonia · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 41482026-04-05 · 19:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-691
    N. Rizvi, S. Peters, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  19. Abstract 11122026-04-05 · 13:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-891 study)
    G. Curigliano, T. Mok, F. Andre, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 58312026-04-03 · 21:00 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with ovarian
    G. Curigliano, J. Brahmer, C. Robert · Cleveland Clinic
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  21. Abstract 49482026-04-04 · 20:00 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for HCC: IMpower-892
    N. Rizvi, M. Reck · Institut Gustave Roussy
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  22. Abstract 99702026-04-01 · 15:45 CT · E450
    KEYNOTE-806: Keytruda (pembrolizumab) 3L+ in SCLC
    F. Andre, H. Rugo, S. Peters, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  23. Abstract 42522026-04-01 · 18:15 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-321
    M.C. Garassino, S. Modi · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  24. Abstract 42262026-04-04 · 14:15 CT · S406
    EV-248: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    S. Modi, H. Borghaei · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  25. Abstract 59652026-04-04 · 20:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-534
    M.C. Garassino, G. Curigliano · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  26. Abstract 46822026-04-04 · 13:30 CT · Hall B1
    ASCENT-545: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    E. Winer, C. Saura, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  27. Abstract 14212026-04-03 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-160 study)
    N. Rizvi, F. Andre, M.C. Garassino, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 44002026-04-03 · 16:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-779
    N. Rizvi, H. Rugo, F. Andre, et al. · University of Chicago
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  29. Abstract 12132026-04-02 · 14:00 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-142
    M. Krop, M. Reck, T. Mok · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 41922026-04-05 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu neoadjuvant for gastric: DESTINY-Breast-19
    S. Antonia, C. Robert, S. Peters · Royal Marsden Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  31. Abstract 43802026-04-02 · 15:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with biliary tract
    J. Cortes, C. Robert · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  32. Abstract 15622026-04-02 · 16:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-842 study)
    M. Reck, F. Andre · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 13802026-04-03 · 18:45 CT · S100A
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-781
    S. Peters, P. Schmid, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 12182026-04-05 · 13:00 CT · S406
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-557
    C. Robert, M. Reck, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 91422026-04-05 · 18:45 CT · S100A
    IMpower-206: Tecentriq (atezolizumab) 3L+ in NSCLC
    S. Modi, M. Krop · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 18302026-04-01 · 13:30 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    J. Brahmer, S. Tolaney, S. Peters, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 53952026-04-04 · 13:15 CT · Arie Crown Theater
    Real-world effectiveness of Lynparza vs standard of care in prostate
    S. Modi, H. Borghaei · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  38. Abstract 17672026-04-05 · 21:00 CT · Hall B1
    IMpower-949: Tecentriq (atezolizumab) adjuvant in TNBC
    J. Cortes, A. Spira, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 59912026-04-02 · 20:15 CT · S100A
    OlympiA-916: Lynparza (olaparib) maintenance in prostate
    A. Spira, H. Rugo, C. Saura, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  40. Abstract 99752026-04-03 · 14:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-197 study)
    E. Winer, J. Brahmer, P. Schmid, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  41. Abstract 19052026-04-03 · 14:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-498
    J. Brahmer, S. Antonia · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 90762026-04-03 · 19:15 CT · E450
    Long-term follow-up of Keytruda 3L+ for NSCLC: KEYNOTE-413
    M.C. Garassino, P. Schmid, F. Andre, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  43. Abstract 15252026-04-05 · 21:00 CT · Hall B1
    MONALEESA-835: Kisqali (ribociclib) 2L in HR+ breast cancer
    N. Rizvi, F. Andre, M. Krop, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 17102026-04-03 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    J. Cortes, T. Mok · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 42522026-04-05 · 18:30 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-762
    P. Schmid, J. Cortes, M. Reck, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  46. Abstract 11352026-04-05 · 21:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-341
    H. Rugo, S. Peters, R. Herbst · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 94252026-04-04 · 20:45 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Tolaney, C. Robert · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  48. Abstract 97072026-04-02 · 13:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    S. Tolaney, M.C. Garassino, R. Herbst · Peter MacCallum Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  49. Abstract 10262026-04-03 · 19:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-245
    S. Peters, J. Brahmer · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 15832026-04-02 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-803
    T. Mok, H. Rugo · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 97252026-04-04 · 14:00 CT · S406
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-239
    M.C. Garassino, A. Spira, J. Cortes, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 95112026-04-01 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-154 study)
    S. Antonia, H. Borghaei, M. Krop, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  53. Abstract 60852026-04-04 · 19:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-347
    S. Tolaney, S. Modi, C. Saura · Massachusetts General Hospital
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  54. Abstract 100032026-04-02 · 20:45 CT · Arie Crown Theater
    KEYNOTE-302: Keytruda (pembrolizumab) neoadjuvant in metastatic melanoma
    N. Rizvi, M. Krop · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  55. Abstract 96452026-04-05 · 16:45 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    E. Winer, M. Reck, M. Krop, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  56. Abstract 10182026-04-01 · 18:15 CT · Hall B1
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-420
    T. Mok, R. Herbst, F. Andre, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 90712026-04-03 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    C. Saura, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  58. Abstract 16802026-04-03 · 13:30 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    S. Modi, C. Saura · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 46312026-04-01 · 20:15 CT · Hall B1
    EV-103: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    H. Borghaei, N. Rizvi, S. Tolaney, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  60. Abstract 10322026-04-05 · 16:30 CT · S406
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-868
    A. Spira, F. Andre, M. Krop · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 47622026-04-02 · 21:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-474
    P. Schmid, S. Tolaney, M. Krop, et al. · Royal Marsden Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  62. Abstract 48232026-04-04 · 20:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-330
    S. Antonia, P. Schmid, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  63. Abstract 43702026-04-04 · 16:15 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for urothelial carcinoma: ASCENT-121
    E. Winer, C. Saura, S. Antonia, et al. · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  64. Abstract 97712026-04-01 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-999 study)
    J. Cortes, H. Rugo · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  65. Abstract 91202026-04-05 · 18:00 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with SCLC
    S. Antonia, M.C. Garassino, H. Rugo, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  66. Abstract 95612026-04-04 · 21:00 CT · S406
    Long-term follow-up of Keytruda adjuvant for metastatic melanoma: KEYNOTE-373
    R. Herbst, S. Modi, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  67. Abstract 13142026-04-02 · 14:15 CT · S100A
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-775
    S. Tolaney, C. Robert, G. Curigliano, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 41232026-04-04 · 14:30 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-177 study)
    M.C. Garassino, T. Mok, S. Modi · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  69. Abstract 18142026-04-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-827 study)
    M. Krop, S. Tolaney, M. Reck, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 16022026-04-01 · 21:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-882
    M.C. Garassino, J. Brahmer, H. Borghaei · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  71. Abstract 102112026-04-01 · 13:45 CT · Hall B1
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-65
    A. Spira, M. Reck · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  72. Abstract 15292026-04-01 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-508 study)
    J. Cortes, P. Schmid · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 13122026-04-04 · 20:30 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    S. Modi, F. Andre, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 93512026-04-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-479 study)
    F. Andre, C. Saura, G. Curigliano · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  75. Abstract 41732026-04-01 · 20:00 CT · S406
    Quality of life outcomes with Opdivo in patients with HCC
    L. Paz-Ares, C. Saura, S. Modi, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  76. Abstract 94162026-04-05 · 15:45 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-257
    S. Peters, G. Curigliano, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  77. Abstract 14662026-04-03 · 15:15 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    C. Robert, P. Schmid · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  78. Abstract 41962026-04-01 · 15:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-588 study)
    S. Modi, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  79. Abstract 95732026-04-02 · 18:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    N. Rizvi, P. Schmid, L. Paz-Ares, et al. · Karolinska Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  80. Abstract 49292026-04-02 · 20:30 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-602 study)
    F. Andre, M. Reck, L. Paz-Ares, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  81. Abstract 52172026-04-03 · 16:00 CT · S406
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-900
    J. Cortes, S. Peters, H. Rugo, et al. · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  82. Abstract 44222026-04-04 · 18:00 CT · S406
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    S. Modi, G. Curigliano, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  83. Abstract 98502026-04-04 · 21:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-458
    L. Paz-Ares, P. Schmid, G. Curigliano · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  84. Abstract 43972026-04-05 · 20:00 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-122
    M. Reck, M. Krop · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  85. Abstract 67762026-04-05 · 14:00 CT · S100A
    KEYNOTE-207: Keytruda (pembrolizumab) adjuvant in RCC
    S. Peters, R. Herbst, M. Reck, et al. · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  86. Abstract 17632026-04-01 · 20:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-224
    J. Cortes, R. Herbst, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 13142026-04-01 · 18:15 CT · S100A
    MONALEESA-197: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    H. Borghaei, S. Tolaney, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 42032026-04-02 · 19:15 CT · S100A
    Quality of life outcomes with Enhertu in patients with gastric
    H. Borghaei, S. Tolaney, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  89. Abstract 62232026-04-04 · 15:30 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    R. Herbst, H. Rugo · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  90. Abstract 10972026-04-04 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-432 study)
    F. Andre, S. Peters · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  91. Abstract 40992026-04-02 · 14:45 CT · Hall B1
    CheckMate-208: Opdivo (nivolumab) 3L+ in HCC
    M. Reck, A. Spira, C. Robert · National Cancer Center Japan
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  92. Abstract 17522026-04-04 · 18:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-237
    S. Peters, E. Winer, P. Schmid, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  93. Abstract 96372026-04-01 · 15:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with NSCLC
    F. Andre, J. Brahmer, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  94. Abstract 60802026-04-01 · 21:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-314 study)
    C. Robert, H. Rugo, M. Krop, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  95. Abstract 11222026-04-05 · 20:45 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Modi, J. Cortes, M.C. Garassino, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 18262026-04-01 · 21:00 CT · S100A
    DESTINY-Breast-682: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    F. Andre, C. Robert · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 63662026-04-04 · 21:15 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-377
    P. Schmid, H. Borghaei, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  98. Abstract 47432026-04-01 · 16:15 CT · S100A
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    S. Modi, T. Mok · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  99. Abstract 102082026-04-04 · 15:15 CT · Hall B1
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-953
    T. Mok, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  100. Abstract 47842026-04-02 · 15:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-977
    J. Brahmer, M.C. Garassino, S. Peters, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  101. Abstract 47912026-04-01 · 19:15 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in gastric
    S. Modi, S. Tolaney · National Cancer Center Japan
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  102. Abstract 103102026-04-01 · 19:00 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    S. Antonia, T. Mok, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  103. Abstract 49122026-04-05 · 18:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-938
    P. Schmid, T. Mok, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  104. Abstract 62752026-04-02 · 19:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-883
    R. Herbst, A. Spira · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  105. Abstract 44232026-04-02 · 18:15 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    J. Brahmer, F. Andre, E. Winer, et al. · Karolinska Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  106. Abstract 11462026-04-02 · 19:30 CT · S100A
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-354
    H. Rugo, S. Modi, M. Krop, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  107. Abstract 17892026-04-01 · 20:30 CT · S100A
    Quality of life outcomes with Keytruda in patients with TNBC
    F. Andre, N. Rizvi, M.C. Garassino · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 42712026-04-03 · 21:30 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-457
    H. Borghaei, T. Mok, S. Tolaney, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  109. Abstract 10362026-04-04 · 16:45 CT · E450
    ASCENT-306: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    H. Borghaei, J. Cortes, F. Andre, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 47862026-04-02 · 18:45 CT · Arie Crown Theater
    PACIFIC-627: Imfinzi (durvalumab) 2L in biliary tract
    H. Borghaei, C. Saura · Peter MacCallum Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  111. Abstract 15752026-04-03 · 16:00 CT · Arie Crown Theater
    MONALEESA-361: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    J. Cortes, C. Saura, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  112. Abstract 96042026-04-02 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-698 study)
    S. Peters, S. Tolaney, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  113. Abstract 17602026-04-02 · 20:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-59
    E. Winer, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 69062026-04-04 · 14:15 CT · S406
    CheckMate-914: Opdivo (nivolumab) 1L in RCC
    T. Mok, N. Rizvi, R. Herbst, et al. · University of Chicago
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  115. Abstract 64582026-04-02 · 21:45 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-227
    C. Saura, L. Paz-Ares · Stanford Cancer Institute
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  116. Abstract 17822026-04-03 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-177 study)
    F. Andre, J. Brahmer, M. Krop · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 48102026-04-05 · 16:15 CT · Arie Crown Theater
    PACIFIC-648: Imfinzi (durvalumab) 3L+ in biliary tract
    H. Borghaei, P. Schmid · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  118. Abstract 56082026-04-01 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-193
    E. Winer, M. Reck, H. Rugo, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  119. Abstract 13322026-04-03 · 18:00 CT · E450
    OlympiA-494: Lynparza (olaparib) 3L+ in HR+ breast cancer
    H. Rugo, T. Mok, M.C. Garassino, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 48422026-04-03 · 20:30 CT · Arie Crown Theater
    IMpower-839: Tecentriq (atezolizumab) maintenance in HCC
    T. Mok, H. Borghaei, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  121. Abstract 90822026-04-01 · 16:00 CT · S100A
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-41
    C. Robert, J. Cortes, C. Saura, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  122. Abstract 12472026-04-05 · 19:00 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-253
    S. Modi, E. Winer, J. Brahmer · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 99602026-04-05 · 19:45 CT · Hall B1
    DESTINY-Breast-714: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    M.C. Garassino, J. Brahmer, L. Paz-Ares · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  124. Abstract 44382026-04-01 · 20:00 CT · E450
    PACIFIC-274: Imfinzi (durvalumab) neoadjuvant in biliary tract
    S. Modi, G. Curigliano, S. Peters · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  125. Abstract 92422026-04-02 · 19:00 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-603 study)
    C. Saura, A. Spira, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  126. Abstract 49362026-04-05 · 15:00 CT · S100A
    IMpower-437: Tecentriq (atezolizumab) neoadjuvant in HCC
    P. Schmid, H. Borghaei, C. Saura, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  127. Abstract 92322026-04-03 · 21:30 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    E. Winer, H. Rugo, S. Peters, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  128. Abstract 17462026-04-02 · 16:45 CT · S406
    MONALEESA-13: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    R. Herbst, G. Curigliano, F. Andre, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  129. Abstract 13412026-04-02 · 16:30 CT · Hall B1
    ASCENT-471: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    C. Saura, S. Modi · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 97392026-04-03 · 20:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-414
    R. Herbst, S. Peters, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  131. Abstract 40792026-04-04 · 19:00 CT · S406
    Long-term follow-up of Opdivo adjuvant for HCC: CheckMate-547
    S. Peters, S. Tolaney, H. Borghaei · University of Chicago
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  132. Abstract 47662026-04-02 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi neoadjuvant for biliary tract: PACIFIC-244
    L. Paz-Ares, M. Krop, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  133. Abstract 16802026-04-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-446 study)
    A. Spira, E. Winer, S. Modi, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 43412026-04-04 · 19:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-747
    A. Spira, R. Herbst · National Cancer Center Japan
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  135. Abstract 12862026-04-05 · 13:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-644 study)
    M. Krop, G. Curigliano, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  136. Abstract 17302026-04-04 · 15:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-514
    S. Antonia, M.C. Garassino · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 13212026-04-04 · 15:15 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-751
    S. Peters, A. Spira, L. Paz-Ares, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 61732026-04-02 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-514 study)
    M.C. Garassino, M. Krop · University of Chicago
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  139. Abstract 19452026-04-05 · 14:45 CT · S406
    MONARCH-108: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    R. Herbst, T. Mok, M. Reck · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  140. Abstract 43552026-04-04 · 13:30 CT · Hall B1
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    H. Rugo, L. Paz-Ares, E. Winer, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  141. Abstract 13942026-04-01 · 18:15 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-734
    C. Robert, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  142. Abstract 91822026-04-04 · 21:00 CT · S100A
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-233
    F. Andre, P. Schmid · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  143. Abstract 47122026-04-04 · 21:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-680
    J. Brahmer, E. Winer, M. Krop · Mayo Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  144. Abstract 91682026-04-02 · 14:15 CT · E450
    IMpower-151: Tecentriq (atezolizumab) 2L in NSCLC
    M. Reck, S. Modi, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  145. Abstract 91262026-04-01 · 15:00 CT · S100A
    IMpower-669: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    L. Paz-Ares, M. Krop · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  146. Abstract 18362026-04-02 · 19:15 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-547
    J. Brahmer, L. Paz-Ares, P. Schmid · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 19932026-04-05 · 16:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-410 study)
    M.C. Garassino, F. Andre, A. Spira, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 54292026-04-02 · 16:30 CT · Arie Crown Theater
    OlympiA-232: Lynparza (olaparib) 2L in prostate
    S. Modi, M. Krop · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  149. Abstract 15932026-04-04 · 18:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-661
    H. Borghaei, J. Brahmer, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 46302026-04-03 · 21:00 CT · E450
    EV-208: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    L. Paz-Ares, J. Cortes, M. Reck, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  151. Abstract 67022026-04-01 · 15:00 CT · E450
    CheckMate-899: Opdivo (nivolumab) neoadjuvant in RCC
    M. Reck, F. Andre, L. Paz-Ares · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  152. Abstract 48212026-04-01 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-922 study)
    L. Paz-Ares, S. Tolaney, H. Borghaei, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  153. Abstract 98422026-04-02 · 14:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-258
    J. Cortes, G. Curigliano, P. Schmid · Mayo Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  154. Abstract 18862026-04-03 · 16:30 CT · S406
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-401
    P. Schmid, J. Brahmer, A. Spira · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  155. Abstract 16872026-04-03 · 18:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-80
    J. Brahmer, E. Winer, R. Herbst, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  156. Abstract 18392026-04-01 · 20:45 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Tolaney, R. Herbst, M.C. Garassino · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  157. Abstract 97382026-04-04 · 19:00 CT · E450
    FLAURA-26: Tagrisso (osimertinib) 1L in NSCLC
    C. Robert, S. Antonia, J. Cortes, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  158. Abstract 91842026-04-04 · 14:00 CT · E450
    PACIFIC-872: Imfinzi (durvalumab) 3L+ in SCLC
    G. Curigliano, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  159. Abstract 48072026-04-02 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-688 study)
    T. Mok, L. Paz-Ares, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  160. Abstract 18742026-04-03 · 15:30 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    M. Reck, N. Rizvi, J. Brahmer · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  161. Abstract 19642026-04-04 · 16:30 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-965
    L. Paz-Ares, M. Reck · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  162. Abstract 44782026-04-01 · 19:45 CT · S406
    ASCENT-913: Trodelvy (sacituzumab govitecan) neoadjuvant in urothelial carcinoma
    F. Andre, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  163. Abstract 65662026-04-01 · 20:45 CT · S406
    Quality of life outcomes with Keytruda in patients with RCC
    T. Mok, C. Saura, H. Borghaei, et al. · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  164. Abstract 11882026-04-03 · 13:30 CT · E450
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-752
    N. Rizvi, A. Spira, C. Saura, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  165. Abstract 19392026-04-01 · 20:15 CT · S406
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-875
    N. Rizvi, M. Krop · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  166. Abstract 98562026-04-03 · 16:45 CT · S406
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-517
    M. Reck, P. Schmid · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  167. Abstract 41022026-04-01 · 16:00 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-499
    L. Paz-Ares, M. Krop, C. Saura · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  168. Abstract 91692026-04-04 · 19:15 CT · S406
    FLAURA-549: Tagrisso (osimertinib) maintenance in NSCLC
    C. Saura, J. Cortes, T. Mok, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  169. Abstract 10382026-04-04 · 13:00 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-942
    L. Paz-Ares, R. Herbst · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  170. Abstract 100612026-04-01 · 15:30 CT · E450
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-60
    G. Curigliano, H. Rugo, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  171. Abstract 91822026-04-02 · 20:15 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-701
    G. Curigliano, S. Tolaney, A. Spira, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  172. Abstract 47112026-04-03 · 18:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-356
    J. Brahmer, S. Modi · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  173. Abstract 68302026-04-02 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-471 study)
    H. Rugo, E. Winer, S. Modi · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  174. Abstract 95252026-04-05 · 13:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-120
    M. Krop, H. Borghaei, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  175. Abstract 40172026-04-01 · 16:15 CT · E450
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-362
    H. Borghaei, M. Reck, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  176. Abstract 42322026-04-02 · 16:45 CT · S406
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-966 study)
    N. Rizvi, T. Mok, S. Peters, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  177. Abstract 17912026-04-02 · 13:30 CT · S406
    OlympiA-403: Lynparza (olaparib) 3L+ in HR+ breast cancer
    F. Andre, M.C. Garassino, C. Robert · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  178. Abstract 96732026-04-03 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-379
    J. Cortes, M. Reck · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  179. Abstract 16432026-04-05 · 20:00 CT · Arie Crown Theater
    PALOMA-821: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    J. Brahmer, M. Reck, S. Modi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  180. Abstract 46312026-04-02 · 16:15 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    T. Mok, H. Borghaei, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  181. Abstract 45072026-04-01 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-350 study)
    M. Reck, C. Saura, G. Curigliano, et al. · Royal Marsden Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  182. Abstract 45792026-04-03 · 19:45 CT · S100A
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-119
    N. Rizvi, G. Curigliano, A. Spira · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  183. Abstract 13542026-04-03 · 14:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-465
    J. Cortes, H. Borghaei, P. Schmid, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  184. Abstract 17422026-04-03 · 18:00 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-885
    C. Saura, F. Andre · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  185. Abstract 66102026-04-05 · 15:30 CT · E450
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-721
    M.C. Garassino, L. Paz-Ares, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  186. Abstract 14352026-04-04 · 18:30 CT · S406
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-490
    J. Cortes, N. Rizvi, T. Mok · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  187. Abstract 97172026-04-02 · 13:15 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-538
    S. Peters, A. Spira · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  188. Abstract 93202026-04-01 · 19:30 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-714
    S. Modi, T. Mok, M. Reck, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  189. Abstract 13782026-04-05 · 13:30 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-31
    L. Paz-Ares, M. Reck, F. Andre · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  190. Abstract 47812026-04-04 · 13:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-995 study)
    S. Peters, G. Curigliano, J. Brahmer, et al. · Mayo Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  191. Abstract 104702026-04-05 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-9 study)
    C. Saura, M.C. Garassino · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  192. Abstract 16892026-04-05 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-986 study)
    C. Saura, J. Cortes, G. Curigliano · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  193. Abstract 58882026-04-02 · 18:15 CT · Hall B1
    OlympiA-456: Lynparza (olaparib) adjuvant in prostate
    F. Andre, T. Mok, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  194. Abstract 13932026-04-05 · 21:30 CT · E450
    PALOMA-845: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    F. Andre, G. Curigliano, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  195. Abstract 17912026-04-01 · 19:45 CT · Hall B1
    OlympiA-315: Lynparza (olaparib) 1L in HR+ breast cancer
    H. Rugo, S. Modi, M. Krop · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  196. Abstract 11382026-04-05 · 14:15 CT · S406
    PALOMA-473: Ibrance (palbociclib) 2L in HR+ breast cancer
    E. Winer, J. Cortes, J. Brahmer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  197. Abstract 12162026-04-04 · 16:45 CT · E450
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-65
    J. Cortes, S. Modi · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  198. Abstract 62472026-04-02 · 19:00 CT · S406
    Long-term follow-up of Lynparza 2L for ovarian: OlympiA-698
    C. Robert, A. Spira · Karolinska Institute
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  199. Abstract 12222026-04-01 · 14:45 CT · S100A
    PALOMA-675: Ibrance (palbociclib) 2L in HR+ breast cancer
    J. Cortes, L. Paz-Ares, G. Curigliano · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  200. Abstract 99882026-04-04 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-610 study)
    S. Peters, L. Paz-Ares, P. Schmid, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.